

NOVO NORDISK A S  
Form 6-K  
May 22, 2013

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

**May 21, 2013**

---

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé**

**DK- 2880, Bagsvaerd**

**Denmark**

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_\_



## Novo Nordisk A/S – Share repurchase programme

**Bagsværd, Denmark, 21 May 2013** – On 3 May 2013, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 14.0 billion to be executed during a 12-month period beginning 31 January 2013.

Under the programme initiated 3 May 2013, Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 6 May 2013 to 6 August 2013.

Since the announcement as of 13 May 2013, the following transactions have been made under the programme:

|  | <b>Number of<br/>shares</b> | <b>Average<br/>purchase price</b> | <b>Transaction<br/>value, DKK</b> |
|--|-----------------------------|-----------------------------------|-----------------------------------|
| <b>Accumulated, last announcement</b>  | <b>131,500</b>              |                                   | <b>129,484,735</b>                |
| 13 May 2013                            | 40,000                      | 992.72                            | 39,708,728                        |
| 14 May 2013                            | 41,000                      | 1,000.02                          | 41,000,820                        |
| 15 May 2013                            | 43,000                      | 1,013.66                          | 43,587,393                        |
| 16 May 2013                            | 50,000                      | 1,001.60                          | 50,080,000                        |
| 17 May 2013                            | 60,000                      | 996.21                            | 59,772,372                        |
| <b>Accumulated under the programme</b> | <b>365,500</b>              |                                   | <b>363,634,048</b>                |

Transactions related to Novo Nordisk’s incentive programmes have resulted in a net sale by Novo Nordisk of 4,875 B shares in the period from 13 May 2013 to 17 May 2013. The shares in these transactions were not part of the Safe Harbour repurchase programme.

**Novo Nordisk A/S**  
Investor Relations

Novo Allé  
2880 Bagsværd  
Denmark

Telephone:  
+45 4444 8888

Internet:  
[www.novonordisk.com](http://www.novonordisk.com)

CVR no:  
24 25 67 90

Company announcement No 37 / 2013

---

With the transactions stated above, Novo Nordisk owns a total of 13,503,148 treasury shares, corresponding to 2.5% of the share capital. The total amount of shares in the company is 550,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 14.0 billion during a 12-month period beginning 31 January 2013. As of 17 May 2013, Novo Nordisk has repurchased a total of 5,977,310 B shares equal to a transaction value of DKK 5,866,345,482.

*Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 35,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com).*

## Further information

### Media:

|                      |                 |  |
|----------------------|-----------------|--|
| Anne Margrethe Hauge | +45 4442 3450   | <a href="mailto:amhg@novonordisk.com">amhg@novonordisk.com</a> |
| Ken Inchausti (US)   | +1 609 514 8316 | <a href="mailto:kiau@novonordisk.com">kiau@novonordisk.com</a> |

### Investors:

|                         |                 |  |
|-------------------------|-----------------|--|
| Kasper Roseeuw Poulsen  | +45 4442 4303   | <a href="mailto:krop@novonordisk.com">krop@novonordisk.com</a> |
| Frank Daniel Mersebach  | +45 4442 0604   | <a href="mailto:fdni@novonordisk.com">fdni@novonordisk.com</a> |
| Lars Borup Jacobsen     | +45 3075 3479   | <a href="mailto:lbpj@novonordisk.com">lbpj@novonordisk.com</a> |
| Jannick Lindegaard (US) | +1 609 786 4575 | <a href="mailto:jlis@novonordisk.com">jlis@novonordisk.com</a> |

**Novo Nordisk A/S**  
Investor Relations  
Novo Allé  
2880 Bagsværd  
Denmark

Telephone:  
+45 4444 8888  
Internet:  
[www.novonordisk.com](http://www.novonordisk.com)

CVR no:  
24 25 67 90



## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: May 21, 2013

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer